The antiangiogenic agent AE 941 [`Neovastat'] provides clinical benefit in prostate cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1295, 2001-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity

By Gingras Denis   Labelle Dominique   Nyalendo Carine   Boivin Dominique   Demeule Michel   Barthomeuf Chantal   Béliveau Richard  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 17-26

Springer Publishing Company

Access to resources Recommend Favorite

AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma

By Bukowski Ronald M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1403-1411

Informa Healthcare

Access to resources Recommend Favorite

Novel triple combo provides added benefit in advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1559, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Satraplatin shows benefit in refractory prostate cancer

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

By >   Pietrantonio Filippo   Martinetti Antonia   Buzzoni Roberto   Gevorgyan Arpine   Bajetta Emilio  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite